Is skin cancer itchy
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Is Skin Cancer Itchy? Understanding the Symptomatology of Skin Cancer
Prevalence of Itch in Skin Cancer
Itch, also known as pruritus, is a common symptom associated with various skin conditions, including skin cancer. Research indicates that itch is a significant symptom in nonmelanoma skin cancers (NMSC), such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). A large clinicopathologic study found that 36.9% of skin cancer patients reported experiencing itch at the time of excision. This symptom is less prevalent in melanomas, suggesting a differentiation in symptomatology between melanoma and nonmelanoma skin cancers.
Itch and Pain in Nonmelanoma Skin Cancer
Nonmelanoma skin cancers, particularly BCC and SCC, are frequently associated with both itch and pain. Studies have shown that the intensity of itch in these cancers correlates with the degree of inflammation and the presence of eosinophils in the inflammatory infiltrate . This suggests that the inflammatory response in the skin plays a crucial role in the sensation of itch. Additionally, pain is more commonly reported in SCC compared to BCC, although no significant difference in itch prevalence between these subtypes has been observed.
Mechanisms Underlying Itch in Skin Cancer
The mechanisms driving itch in skin cancer are complex and involve various neuroimmune pathways. Recent studies have highlighted the role of specific mediators in the sensation of itch. For instance, immunohistochemistry analyses have identified certain mediators involved in the itch and pain pathways in NMSC. Furthermore, the presence of eosinophils and the degree of inflammation are significant factors contributing to the intensity of itch.
Paraneoplastic Itch and Malignancy-Associated Pruritus
Paraneoplastic itch, a term used to describe itch associated with cancer, can occur in patients with both hematological and solid tumor malignancies. Although it is considered rare, it is more frequently observed in lymphoproliferative malignancies such as Hodgkin's lymphoma and polycythemia vera . In the context of skin cancer, malignancy-associated pruritus is most commonly linked to nonmelanoma skin cancers, affecting more than one-third of patients. This type of itch can significantly impair the quality of life and is often resistant to conventional treatments.
Clinical Implications and Assessment
Given the prevalence and impact of itch in skin cancer, it is crucial for dermatologic surgeons and clinicians to assess this symptom during patient evaluations. Implementing a numerical rating scale for itch and pain can aid in the early identification and management of cutaneous malignancies, particularly in high-risk populations such as transplant recipients. Recognizing the clinical manifestations of pruritus and pain can enhance screening and improve patient outcomes.
Conclusion
Itch is a notable symptom in nonmelanoma skin cancers, with a significant proportion of patients experiencing this discomfort. The intensity of itch is closely linked to the inflammatory response within the skin. Understanding the underlying mechanisms and clinical implications of itch in skin cancer can aid in better diagnosis and management, ultimately improving patient care.
Sources and full results
Most relevant research papers on this topic